hepatocellular carcinoma (HCC)
Conditions
Interventions
Experimental group:iNKT cells infusion combined with lenvatinib
Sponsors
Beijing You'an Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years, no gender limit. 2. All the cases were hepatocellular carcinoma clinically or pathologically confirmed by CT, nuclear magnetic imaging, etc., with stage C BCLC, initial treatment or progress since the last anti-tumor therapy. 3. Expected survival >12 weeks. 4. Other indicators: white blood cell count >=3x10^9/L; Absolute lymphocyte count >=0.8x10^9/L; Hemoglobin >=85 g/L; Platelet count >=50x10^9/L; Serum creatinine < 1.5x upper limit of normal. 5. At least 10 iNKT cells /ml were detected by flow cytometry in patients' peripheral blood. 6. Understand and voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Uncontrollable systemic diseases such as hypertension, heart disease history, etc. 2. The presence of portal vein main cancer thrombus, central nervous system tumor metastasis or other tumors. 3. Within 4 weeks before the study (blood collection), radiotherapy and chemotherapy for the disease under study, local therapy, and targeted antitumor drugs were used. 4. With unstable immune system or infectious disease. 5. Infected with syphilis and HIV. 6. Patients with a history of stem cell transplantation or organ transplantation. 7. Allergic to immunotherapy and related drugs. 8. There are liver disease related complications requiring treatment: moderate or severe pleural effusion, pericardial effusion, ascites, upper gastrointestinal bleeding. 9. Pregnant and lactating patients. 10. The clinician considers it inappropriate to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease Control Rate (DCR);Progression-Free Survival(PFS);Safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| Inkt-related Immune Response Indicators;Alpha-fetoprotein; | — |
Countries
China
Contacts
Public ContactXiong Fang
Beijing You'an Hospital, Capital Medical University
Outcome results
None listed